Slides
Page 1
Optomed Q1 2025 6th May 2025 Juho Himberg, CEO Sakari Knuutti, CFO
Page 2
3. Positive cashflow from operating activities continued and strong cash position 2. Software Segment grew steadily 2.4% 1. Devices segment revenue up by 72% driven by the US Highlights Q1
Page 3
Q1-2025 Key Figures STRONG QUARTER - Q1 CONTINUED THE GOOD TREND OF Q4 Q1/2025 Q1/2024 Change Revenue 4,021 3,327 20.9% Gross profit 2,693 2,213 21.7% Gross margin 67.0% 66.5% +5pps Adjusted EBITDA -737 -648 -13.7% Adjusted EBITDA margin -18.3% -19.5% +12pps Net profit / loss -1,581 -1,090 -44.9% Earnings per share -0.08 -0.06 -29.5% Cash flow from operating activities 371 -515 172.1%
Page 4
Segment highlights
Page 5
Q1/2025 Q1/2024 Change Revenue 1,526 890 71.5% Gross profit 897 516 74.0% Gross margin 58.8% 58.0% +8pps EBITDA -297 -361 17.5% EBITDA margin -19.5 % -40.5 % +210pps Devices Segment Q1-2025 OUR TOPLINE GREW 72 % Revenue surged driven by the US sales growth.1. Aurora AEYE continues to scale steadily in both adoption and usage. 2. Our next generation camera product is set to launch in Q2 3.
Page 6
Software Segment Q1-2025 THE SOFTWARE SEGMENT CONTINUED WITH ITS STEADY CONTRIBUTION Q1/2025 Q1/2024 Change Revenue 2,496 2,437 2.4% Gross profit 1,796 1,697 5.8% Gross margin 72.0% 69.6% +24pps EBITDA 521 526 -0.9 % EBITDA margin 20.9 % 21.6 % -7pps Healthcare revenue increased but the increase was partly offset by the decline of non-healthcare consulting revenue. The staff cost increased slightly due to increased headcount 1. 2.
Page 7
Cash Flow Q1-2025 CASH POSITION AT EUR 9.7 MILLION • Positive net cash from operating activities supported by changes in net working capital • Cash position remains strong at EUR 9.7 million (5.7) • Trade policy and forex changes are under close surveillance Q1 2025 Q1 2024 Loss for the financial year -1,581 -1,090 Cash flows before change in net working capital -692 -596 Change in net working capital 1,101 127 Cash flows before finance items 410 -468 Cash flows from finance items -38 -47 Net cash from operating activities 371 -515 Net cash used in investing activities -781 -534 Net cash from financing activities -357 -366 Net increase (decrease) in cash and cash equivalents -767 -1,415 Cash and cash equivalents at the beginning of period 10,467 7,118 Cash and cash equivalents at end of period 9,688 5,706
Page 8
Outlook 2025 Outlook 2025: Optomed expects its full year 2025 revenue to grow strongly compared to 2024. Key items supporting our growth: • Increased adoption of AI-powered screening solutions, particularly in the U.S. following the FDA clearance • New partnerships and collaborations with healthcare providers and research institutions • Continued innovation and investment in AI and handheld imaging technology • Strong Q1 Key unknowns: • Challenges to accurately forecast the timing and size of large deals due to various uncertainties and market dynamics • Blue ocean market & sales cycles • Geopolitics • Tough comparables in Q4
Page 9
Summary • Strong start for the year 2025 • Aurora AEYE continues to scale steadily in both adoption and usage. • New product launch expected in Q2 • Optomed expects its full year 2025 revenue to grow strongly compared to 2024.
Page 10
Appendix
Page 11
Balance Sheet • Equity ratio of 73.0 (69.5) percent • Total borrowings of EUR 2.1 (3.1) million • Net working capital was EUR 188 (2,364) • Interest-bearing net debt totaled EUR -7,621 (-2,585) thousand. 31 March 2025 31 March 2024 ASSETS Goodwill 4,256 4,256 Development costs 8,487 7,996 Other intangible assets 1,323 1,680 Total intangible assets 14,066 13,932 Total tangible assets 857 652 Total non-current assets 16,318 15,936 Inventories 1,713 2,777 Trade and other receivables 3,046 3,259 Cash and cash equivalent 9,688 5,706 Total current assets 14,447 11,742 TOTAL ASSETS 30,765 27,678 LIABILITIES Total equity 22,470 19,223 Non-current liabilities 2,243 3,228 Total current liabilities 6,052 5,227 TOTAL EQUITY AND LIABILITIES 30,765 27,678